uniQure N.V. Cash and Cash Equivalents
uniQure N.V. (QURE) had Cash and Cash Equivalents of $139.99 million as of 2026-03-31, per its 10-Q filed 2026-05-05.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-05-05
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $139.99M.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $80.24M.
- 2025-09-30: Cash and Cash Equivalents, at Carrying Value $597.06M.
- 2025-06-30: Cash and Cash Equivalents, at Carrying Value $253.78M.
| Period end | Cash and Cash Equivalents, at Carrying Value |
|---|---|
| 2026-03-31 | $139.99M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $80.24M 10-Q · filed 2026-05-05 |
| 2025-09-30 | $597.06M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $253.78M 10-Q · filed 2025-07-29 |
| 2025-03-31 | $217.23M 10-Q · filed 2026-05-05 |
| 2024-12-31 | $158.93M 10-K · filed 2026-03-02 |
| 2024-09-30 | $251.63M 10-Q · filed 2025-11-10 |
| 2024-06-30 | $287.88M 10-Q · filed 2025-07-29 |
| 2024-03-31 | $243.06M 10-Q · filed 2025-05-09 |
| 2023-12-31 | $241.36M 10-K · filed 2026-03-02 |
| 2023-09-30 | $229.48M 10-Q · filed 2024-11-05 |
| 2023-06-30 | $513.60M 10-Q · filed 2024-08-01 |
| 2023-03-31 | $153.85M 10-Q · filed 2024-05-07 |
| 2022-12-31 | $228.01M 10-K · filed 2025-02-27 |
| 2022-09-30 | $440.31M 10-Q · filed 2023-11-07 |
| 2022-06-30 | $500.52M 10-Q · filed 2023-08-01 |
| 2022-03-31 | $524.89M 10-Q · filed 2023-05-09 |
| 2021-12-31 | $556.26M 10-K · filed 2024-02-28 |
| 2021-09-30 | $578.46M 10-Q · filed 2022-11-02 |
| 2021-06-30 | $677.33M 10-Q · filed 2022-08-08 |
| 2021-03-31 | $260.81M 10-Q · filed 2022-05-02 |
| 2020-12-31 | $244.93M 10-K · filed 2023-02-27 |
| 2020-09-30 | $279.49M 10-Q · filed 2021-10-25 |
| 2020-06-30 | $314.26M 10-Q · filed 2021-07-26 |
| 2020-03-31 | $342.03M 10-Q · filed 2021-05-10 |
| 2019-12-31 | $377.79M 10-K · filed 2022-02-25 |
| 2019-09-30 | $403.16M 10-Q · filed 2020-10-27 |
| 2019-06-30 | $184.09M 10-Q · filed 2020-07-30 |
| 2019-03-31 | $208.79M 10-Q · filed 2020-04-29 |
| 2018-12-31 | $234.90M 10-K · filed 2021-03-01 |
| 2018-09-30 | $239.55M 10-Q · filed 2019-10-28 |
| 2018-06-30 | $259.18M 10-Q · filed 2019-07-29 |
| 2018-03-31 | $140.82M 10-Q · filed 2019-04-29 |
| 2017-12-31 | $159.37M 10-K · filed 2020-03-02 |
| 2017-09-30 | $88.93M 10-Q · filed 2018-11-06 |
| 2017-06-30 | $104.09M 10-Q · filed 2018-08-08 |
| 2017-03-31 | $120.27M 10-Q · filed 2018-04-30 |
| 2016-12-31 | $132.50M 10-K · filed 2019-02-28 |
| 2016-09-30 | $157.55M 10-Q · filed 2017-11-01 |
| 2016-06-30 | $183.93M 10-Q · filed 2017-08-08 |
| 2016-03-31 | $209.68M 10-Q · filed 2017-05-09 |
| 2015-12-31 | $221.63M 10-K · filed 2018-03-14 |
| 2014-12-31 | $64.69M 10-K · filed 2017-03-15 |
| 2013-12-31 | $32.78M 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |